Aktuellt
SENASTE
Redeye is interested to learn more about today’s news from Alzecure. The release states that an exploratory analysis from its phase I “MAD” trial with ACD856, which targets mainly symptomatic Alzheimers, indicates that the drug candidate increases EEG activity in the brain, which in combination with the recent data on blood-brain-barrier penetration together are interesting early efficacy signals. We hope to learn more about this data and the future clinical program for ACD856 later this year.
LÄS MER
